About Lung-MAP: Leadership

Lung-MAP Partners
Leadership
This diverse, collaborative approach, with support from leading lung cancer advocacy organizations, helps to ensure that the needs of patients, clinicians, developers, and regulators are all considered in the design and operation of the trial.

– Ellen Sigal, Ph.D., Chair and Founder, Friends of Cancer Research
LUNG-MAP Study Chairs
  • SWOG: Roy S. Herbst, M.D., Ph.D.
  • (Vice Chair) Jyoti Patel, M.D.
Medical Oncology Chairs/Champions
  • SWOG: David R. Gandara, M.D.
  • Alliance: Konstantin Dragnev, M.D.
  • Alliance: Jyoti D. Patel, M.D.
  • ECOG-ACRIN: Joel Neal, M.D.
  • ECOG-ACRIN: Ticiana Leal, M.D.
  • NRG: Martin Edelman, M.D.
  • NRG: Saiama Waqar, M.D.
Lung Cooperative Group Chairs
  • SWOG: Karen Kelly, M.D.
  • Alliance: Thomas Stinchcombe, M.D.
  • ECOG-ACRIN: Suresh Ramalingam, M.D.
  • NRG: Jeff Bradley, M.D.
Translational Medicine Chairs
  • SWOG: Fred Hirsch, M.D., Ph.D.
  • SWOG: Philip C. Mack, Ph.D.
  • Alliance: David Kozono, MD, PhD
Biostatisticians
  • Mary Redman, Ph.D.
  • Katherine Minichiello, M.S.
  • Jieling Miao, M.S.
  • James Moon, M.S.
  • Lu Qian, M.S.
Imaging Chairs
  • SWOG/Alliance: Lawrence H. Schwartz, M.D.
LUNG-MAP Trial Oversight Committee
  • SWOG: (Co-Chair) Roy Herbst, Chief of Medical Oncology, Yale Cancer Center
  • (Co-Chair) Ellen Sigal, Chairperson and Founder, Friends of Cancer Research
  • (Co-Chair) Vincent Miller
  • Renzo Canetta, Former Vice President, Global R&D Oncology Policy, BMS
  • Bryan Faller, Missorui Baptist Medical Center
  • Gwen Fyfe, Former Vice President, Oncology Department, Genentech
  • Gary Gilliland, President and Director, Fred Hutchinson Cancer Research Center
  • Gary Kelloff, Special Advisor, NCI-DCTD
  • Lisa LaVange, University of North Carolina
  • Christine Lovly, Vanderbilt University Medical Center
  • Vipul Pareek, University of Oklahoma Health Sciences Center
  • Frances A. Shepherd, CCTG, Princess Margaret Cancer Centre
  • Liza Villaruz, University of Pittsburgh Cancer Institute
  • Janet Woodcock, Director, CDER, FDA
LUNG-MAP Drug Selection Committee
  • ECOG: (Chair) Hossein Borghaei, D.O., M.S., Chief, Division of Thoracic Medical Oncology, Fox Chase Cancer Center

Voting members include representatives from each of the participating NCTN groups, FDA, NCI, Friends of Cancer Research, FNIH, key opinion leaders from academia, and drug developers from industry (retired, consultants, or not from companies participating or potentially participating in Lung-MAP).

LUNG-MAP Public Affairs Committee
  • (Chair) Ryan Hohman, JD, Vice President – Public Affairs, Friends of Cancer Research
  • (Vice Chair) Frank DeSanto, Communications and Public Relations Manager, SWOG
  • Abbey Meltzer, M.P.S., Vice President of Communications and Events, FNIH
NIH/NCI
  • Mike Miller, Senior Science Writer, NCI
  • Lynn Cave, Scientific Program Analyst, NCI-CTEP
  • Holly Massett, PhD, Senior Behavioral Science Analyst, NCI-CTEP
Lung-MAP Advocate Advisors
  • Laurie Fenton-Ambrose, President & CEO, Lung Cancer Alliance
  • Andrea Stern Ferris, President and Chairman, LUNGevity
  • David LeDuc, CFRE, Program Director, Free to Breathe
  • David Simpkins, MS, Vice President, Strategic Communications Planning, American Cancer Society
  • Scott Santarella, President and CEO, Addario Lung Cancer Foundation
  • Delia Naughton, Interim Vice President, Business Development, Lung Cancer Research Foundation
  • Anastasia Hagan, Acting Executive Director, Uniting Against Lung Cancer
  • Harold Wimmer, President & CEO, American Lung Association
This diverse, collaborative approach, with support from leading lung cancer advocacy organizations, helps to ensure that the needs of patients, clinicians, developers, and regulators are all considered in the design and operation of the trial.

– Ellen Sigal, Ph.D., Chair and Founder, Friends of Cancer Research